Navigation Links
BUSM researcher awarded 2 NIH grants totaling over $11 million
Date:11/2/2011

(Boston) - Boston University School of Medicine (BUSM) researcher Robert Lafyatis, MD, recently was awarded two grants from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases. A 5-year, $8 million Centers of Research Translation (CORT) (P50) grant as well as a 5-year $3.3 million (P30) grant. Funding from both grants will be used to study systemic sclerosis (SSc) also known as scleroderma, a rare and complex rheumatic disease involving widespread scarring and vascular disease within multiple organ systems.

SSc remains one of the most difficult rheumatic diseases to manage, with limited effective therapies. These projects were designed to coordinate multiple scientists and clinicians to accelerate the understanding of the disease process through interactive patient-oriented studies into markers of disease activity, investigation of pathogenesis and trials of novel therapeutics.

The P50 grant will fund clinical research, identifying new paradigms for early phase clinical trials and molecular research into scleroderma pathogenesis. The P30 will allow the researchers at four sites: BUSM, University of Pittsburg Medical Center, Northwestern School of Medicine and Dartmouth Medical Center, to set up core services for scleroderma research, with the ultimate goal being a national resource for investigators studying scleroderma across the country.

One of the greatest impediments to finding new treatments is the heterogeneity of patient presentation and disease progression. Clinical markers are unable to predict onset and/or progression of the major complications, such as progressive fibrotic skin disease, pulmonary arterial hypertension and interstitial lung disease, each seen in a minority of SSc patients.

According to the researchers, identification of biomarkers permitting early recognition of these complications would potentially permit more targeted therapies, but also provide "at risk" populations for enrolling in therapeutic trials.

"Empowered by a very large SSc clinical population, we propose careful clinical evaluations, coupled with robust molecular approaches to identify skin, serum and peripheral blood mononuclear cell disease biomarkers," explained principal investigator Lafyatis, who also is a professor of medicine at BUSM.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Tiny fruit fly could offer big clues in fight against obesity, researcher says
6. Researchers create drug to keep tumor growth switched off
7. MSU researcher linking breast cancer patients with alternative therapies
8. UT researcher receives $2.4 million to research obesity, high-risk pregnancy
9. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
10. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
11. Clemson researchers develop hands-free texting application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... locally owned insurance agency which serves Lawrenceville, New Jersey and the surrounding area, ... , Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease ...
(Date:1/19/2017)... ... January 19, 2017 , ... Attorney Robert “RC” Pate , founder ... money to the Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed ... James saw firsthand the effect of the critical funding gap for research into pediatric ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... Reproductive Endocrinologists at Reproductive Medicine Associates of Connecticut (RMACT) have earned “Top ... Cynthia Murdock and Dr. Shaun Williams have each been chosen by their peers ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Bill Howe ... collaboration with the American Heart Association; “Howe” Healthy is Your Heart Drawing Contest ... healthy and active. Each year, Bill Howe Plumbing, Heating & Air receives over 600 ...
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures ... **An FDAnews Webinar**, Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, ... Century Cures Act in order to thrive this year? , The passage of the ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... India , January 18, 2017 ... Imaging Technologies Market by Type: Global Opportunity Analysis and Industry ... size was valued at $2,544 million in 2015 and is ... CAGR of 8.4% from 2016 to 2022. North ... accounted for over three-fourths market share in 2015. Ionizing breast ...
(Date:1/18/2017)... Jan. 18, 2017   Spotlight Innovation Inc. ... Therapeutics plans, in the second quarter of 2017, ... roll-on intended to provide relief from chronic pain, ... analgesics. It was developed under a licensing agreement ... products derived from snake venom. Additionally, Caretta Therapeutics ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017  Dermata ... innovative products to treat a variety of dermatological ... lead compound DMT210, in a Phase 2 acne ... developed to downregulate the proinflammatory cytokines in the ... in acne rosacea. This clinical ...
Breaking Medicine Technology: